Aptamer Group December 2018
19th December 2018
This month:
- Aptamer Group data on selective cell based biomarker aptamers
- The year in review, from new product launches to company accolades
- Interesting applications in international diagnostics and small molecule lateral flow assays
Novel Solutions – Biomarkers
Aptamers specific to the same cell type at different stages within a disease cycle
- No biomarker abundance restriction
- Whole cell targets
- Ease of labelling
The Year in Review
Aptamer Group is proud of the successes we have had this year, and we look forward to new challenges in 2019:
- Launch of OptimerTM, better is our new standard
- Guest Editor for a special issue of Chemosensors – Aptamer Technologies
- Expanding our board, research and development team, office and laboratory space, and establishing USA sales and marketing presence
- Authors on Targeted Treatment aptamer drug conjugate article in European Biopharmaceutical Review
- Multiple licensing agreements in diagnostic and therapeutic markets
- Four PhD’s awarded to AG scientists
- $2.2M Series A investment
- Launch of our AGARO program for academic researchers
- Winner of the CEO Today United Kingdom award
In Review and News
UNICEF Innovation bringing lower cost aptamer diagnostics
In collaboration with Rhodes University’s Biotechnology Research Group tests for Malaria, HIV treatment efficiency, and pregnancy are being developed
Cortisol aptamer in lateral flow assay
Detection of the key hormone cortisol using Au nanoparticles functionalised with cortisol-selective aptamers as a convenient and low cost POC sweat-based sensor for cortisol and other stress biomarkers.
Explore website Resource library Sign up to our Newsletter